Literature DB >> 8492004

A review of oxycodone's clinical pharmacokinetics and pharmacodynamics.

R Pöyhiä, A Vainio, E Kalso.   

Abstract

Oxycodone (14-hydroxy-7,8-dihydrocodeinone) is a strong opioid agonist that is available alone or in combination with mild analgesics. It is suitable for oral administration due to high bioavailability (60%), and may also be given intramuscularly, intravenously, subcutaneously, and rectally; it is not recommended for spinal administration. In analgesic potency, oxycodone is comparable to morphine. With the exception of hallucinations, which may occur more rarely after oxycodone than after morphine, the side effects of these drugs are closely related. The abuse potential of oxycodone is equivalent to that of morphine. The usual indications for oxycodone are severe acute postoperative or posttraumatic pain and cancer pain. When oxycodone is administered, the same precautions should be taken as with morphine or other agonist opioids.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8492004     DOI: 10.1016/0885-3924(93)90101-z

Source DB:  PubMed          Journal:  J Pain Symptom Manage        ISSN: 0885-3924            Impact factor:   3.612


  35 in total

Review 1.  Contribution to variability in response to opioids.

Authors:  Geoffrey W Hanks; Colette Reid
Journal:  Support Care Cancer       Date:  2004-12-10       Impact factor: 3.603

Review 2.  Oxycodone/paracetamol: a low-dose synergic combination useful in different types of pain.

Authors:  Antonio Gatti; Elisabetta Sabato; Anna Rita Di Paolo; Massimo Mammucari; Alessandro Fabrizio Sabato
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.

Authors:  C F Samer; Y Daali; M Wagner; G Hopfgartner; C B Eap; M C Rebsamen; M F Rossier; D Hochstrasser; P Dayer; J A Desmeules
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 4.  Oxycodone for pain in fibromyalgia in adults.

Authors:  Helen Gaskell; R Andrew Moore; Sheena Derry; Cathy Stannard
Journal:  Cochrane Database Syst Rev       Date:  2016-09-01

5.  Comparison of the pharmacokinetics of oxycodone and noroxycodone in male dark agouti and Sprague--Dawley rats: influence of streptozotocin-induced diabetes.

Authors:  Lillian Huang; Stephen R Edwards; Maree T Smith
Journal:  Pharm Res       Date:  2005-07-29       Impact factor: 4.200

6.  No pain relief from morphine? Individual variation in sensitivity to morphine and the need to switch to an alternative opioid in cancer patients.

Authors:  Julia Riley; Joy R Ross; Dag Rutter; Athol U Wells; Katherine Goller; Ron du Bois; Ken Welsh
Journal:  Support Care Cancer       Date:  2005-06-11       Impact factor: 3.603

7.  Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.

Authors:  Shu-Feng Zhou
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

Review 8.  Oxycodone for neuropathic pain in adults.

Authors:  Helen Gaskell; Sheena Derry; Cathy Stannard; R Andrew Moore
Journal:  Cochrane Database Syst Rev       Date:  2016-07-28

9.  Buprenorphine/naloxone as a promising therapeutic option for opioid abusing patients with chronic pain: reduction of pain, opioid withdrawal symptoms, and abuse liability of oral oxycodone.

Authors:  Perrine Roux; Maria A Sullivan; Julien Cohen; Lionel Fugon; Jermaine D Jones; Suzanne K Vosburg; Ziva D Cooper; Jeanne M Manubay; Shanthi Mogali; Sandra D Comer
Journal:  Pain       Date:  2013-05-07       Impact factor: 6.961

Review 10.  Cytochrome P450-mediated changes in oxycodone pharmacokinetics/pharmacodynamics and their clinical implications.

Authors:  Karin C Söderberg Löfdal; Marine L Andersson; Lars L Gustafsson
Journal:  Drugs       Date:  2013-05       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.